Monopar Therapeutics Inc. (MNPR)
After hours:
| Previous Close | 19.71 |
| Open | 19.88 |
| Bid | 19.39 x 100 |
| Ask | 20.28 x 100 |
| Day's Range | 19.54 - 20.20 |
| 52 Week Range | 1.37 - 38.50 |
| Volume | |
| Avg. Volume | 1,244,129 |
| Market Cap | 106.084M |
| Beta (5Y Monthly) | 1.10 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.98 |
| Earnings Date | Nov 08, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 27.33 |
GlobeNewswireMonopar Therapeutics Reports Third Quarter 2024 Financial Results and Recent Developments
In-licensed ALXN-1840 (a Late-Stage Wilson Disease Drug Candidate) from Alexion, AstraZeneca Rare DiseaseTwo Novel Radiopharma Clinical Trials now Active and Enrolling Patients with Advanced Solid Cancers WILMETTE, Ill., Nov. 08, 2024 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (“Monopar” or the “Company”) (Nasdaq: MNPR), a clinical-stage biotechnology company focused on developing innovative treatments for patients with unmet medical needs, today announced third quarter 2024 financial results
- GlobeNewswire
Monopar Therapeutics Inc. Announces Closing of $19.2 Million Public Offering of Common Stock
WILMETTE, Ill., Oct. 30, 2024 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR) (“Monopar Therapeutics” or the “Company”), a clinical-stage biotechnology company focused on developing innovative treatments for patients with unmet medical needs, today announced the closing of its previously announced best efforts public offering of shares of its common stock at a public offering price of $16.25 per share, for aggregate gross proceeds of approximately $19.2 million, before deducting the
